Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as ARO-MAPT-SC
ARO-MAPT · 1 trial · 4 indications
| Arm | Type | Description |
|---|---|---|
| ARO-MAPT-SC | EXPERIMENTAL | ARO-MAPT-SC injection |
| Placebo | PLACEBO_COMPARATOR | Sterile normal saline (0.9%) |
| Name | Type | Description |
|---|---|---|
| ARO-MAPT-SC | DRUG | • single or multiple doses of ARO-MAPT-SC by subcutaneous (SC) injection |
| Placebo | DRUG | • calculated volume to match active treatment by SC administration |
Inclusion Criteria (All Participants): * Body mass index between 18.0 and 35.0 kilograms (kg)/square meter (m\^2) at Screening * Not pregnant or breast-feeding * Able and willing to provide written informed consent prior to the performance of any trial specific procedures * Participants of childbea...
Top 20 of 30 competitors
ARO-MAPT is an investigational RNA-based therapy being developed for Alzheimer disease. It is also being studied in primary tauopathies, including frontotemporal dementia and progressive supranuclear palsy. It is in Phase 1/2 clinical development and is not approved for any use.
ARO-MAPT targets MAPT, the gene that encodes tau protein. As an RNA-based therapy, it is designed to act on MAPT RNA. The Phase 1/2 trial enrolls healthy participants and participants with early Alzheimer disease or primary tauopathies.
ARO-MAPT is being developed by Arrowhead Pharmaceuticals, Inc., which trades on Nasdaq under the ticker ARWR. The company is running the program as an RNA-based therapy in its neurology portfolio, with Alzheimer disease as the lead indication.
ARO-MAPT is in Phase 1/2 clinical development. It is investigational and has not been approved by the FDA or any other regulator. The single active trial is a combined Phase 1/Phase 2 study that is currently recruiting participants.
ARO-MAPT is being studied in trial NCT07221344, titled a trial of ARO-MAPT-SC in healthy participants and participants with early Alzheimer's disease or primary tauopathies. The trial is recruiting, is placebo-controlled and double-blind, and plans to enroll 160 participants across Canada and New Zealand.
Yes, ARO-MAPT-SC is another name for ARO-MAPT. The Phase 1/2 trial NCT07221344 uses the ARO-MAPT-SC designation in its title, and both names refer to the same investigational RNA-based therapy targeting MAPT being developed by Arrowhead Pharmaceuticals.